Company intelligence / Profile preview

Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology

Zhuhai, Guangdong, Chinasg.linkedin.com ↗

Ownership: Private
Development stage: Other

Overview

Jiaheng has submitted applications to the National Medical Products Administration of China for both a combination small molecule therapy targeting type 2 diabetes mellitus and a proprietary traditional Chinese medicine formulation targeting influenza. The company is actively developing both modern pharmaceuticals and innovative TCM products with several programs in clinical or regulatory stages.

Therapeutic areas: EndocrinologyInfectious Diseases
Modalities: Herbal medicineSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology.

Explore the full profile